Immatics (IMTX) Invested Capital (2020 - 2025)
Immatics (IMTX) posted Invested Capital of $20.1 million for Q3 2022, down 34.29% sequentially from $30.7 million in Q2 2022, and down 34.93% YoY from $31.0 million in Q3 2021.
Analysis
Immatics (IMTX) Invested Capital (2020 - 2025) Analysis & Trends
Immatics has reported Invested Capital for 4 years, with the latest figure at $20.1 million in Q3 2022.
- Quarterly Invested Capital fell 34.93% year-over-year to $20.1 million in Q3 2022, while the trailing twelve-month figure through Jun 2023 was $20.1 million (down 83.26% YoY) and the FY2021 annual result came in at $47.6 million, up 49.47% from the prior year.
- Invested Capital fell to $20.1 million in Q3 2022 per IMTX's latest filing, from $30.7 million in the prior quarter.
- Over five years, Invested Capital peaked at $162.2 million in Q1 2020 and troughed at $9.3 million in Q4 2019.
- A 4-year average of $40.5 million and a median of $30.8 million in 2021 frame the typical range for Invested Capital.
- The sharpest annual moves came in 2020 and 2021: Invested Capital soared 258.83% in 2020, then slumped 86.55% in 2021.
- Over 4 years, Invested Capital stood at $9.3 million in 2019, then jumped by 258.83% to $33.2 million in 2020, then soared by 38.37% to $46.0 million in 2021, then slumped by 56.2% to $20.1 million in 2022.
- According to Business Quant data, Invested Capital over the past three periods registered $20.1 million, $30.7 million, and $12.7 million for Q3 2022, Q2 2022, and Q1 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 562.41 Mn |
| Sep 30, 2022 | 134.13 Mn |
| Jun 30, 2022 | 148.38 Mn |
| Mar 31, 2022 | 142.89 Mn |
| Dec 31, 2021 | 59.40 Mn |
| Sep 30, 2021 | 72.43 Mn |
| Dec 31, 2020 | 124.30 Mn |
| Mar 31, 2020 | 162.17 Mn |